Mitler M M
Scripps Clinic and Research Foundation, La Jolla, California.
Sleep. 1994 Dec;17(8 Suppl):S103-6. doi: 10.1093/sleep/17.suppl_8.s103.
This paper briefly reviews sleep laboratory studies on the treatment efficacy of methylphenidate, pemoline, dextroamphetamine and methamphetamine. The literature indicates that 1) methylphenidate, dextroamphetamine, pemoline and methamphetamine objectively improve somnolence as measured by the Multiple Sleep Latency or Maintenance of Wakefulness Tests (MSLT or MWT); 2) pemoline, at doses up to 112.5 mg, is less effective in controlling somnolence than methylphenidate, dextroamphetamine and methamphetamine; 3) there are dose-dependent improvements in performance that parallel MSLT and MWT data; and 4) at the highest doses of stimulants studied to date, narcoleptics, although improved, still did not function on MSLT or MWT and most performance tests at levels comparable to those of control subjects. Future research designs should address issues of placebo effect, practice effects and the degree to which alertness and performance measures can be pharmacologically brought up to levels comparable to those of normal control subjects.
本文简要回顾了关于哌甲酯、匹莫林、右旋苯丙胺和甲基苯丙胺治疗效果的睡眠实验室研究。文献表明:1)通过多次睡眠潜伏期试验或清醒维持试验(MSLT或MWT)测量,哌甲酯、右旋苯丙胺、匹莫林和甲基苯丙胺能客观改善嗜睡症状;2)剂量高达112.5毫克时,匹莫林在控制嗜睡方面不如哌甲酯、右旋苯丙胺和甲基苯丙胺有效;3)在表现方面存在剂量依赖性改善,这与MSLT和MWT数据一致;4)在迄今为止研究的最高剂量兴奋剂作用下,发作性睡病患者虽有改善,但在MSLT或MWT以及大多数表现测试中,其功能仍无法达到与对照受试者相当的水平。未来的研究设计应解决安慰剂效应、练习效应以及警觉性和表现测量在药理学上能提高到与正常对照受试者相当水平的程度等问题。